Class summary at a glance.

Every drug in the Azole Antifungal class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 20tracked in Part D
CY24 Part D spend: $501.4Mcombined across class
Total Rx claims: 14.3M8.0M unique beneficiaries
Generic mfrs (active): 98across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Efinaconazole

Brand: JUBLIA · 154K Part D claims (CY24) · 59K beneficiaries · First FDA approval: 2014-06-06

3 generic mfrs 2 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $179.1M

Class share

36%

of class CY24 spend

View profile →

Ketoconazole

Brand: Ketodan · 6.5M Part D claims (CY24) · 3.3M beneficiaries · First FDA approval: 1999-06-15

12 generic mfrs 75 plans require PA

Low NADAC$0.080

→

Avg plan cost$0.673

Part D spend $122.7M 8× spread, current vs floor

Class share

24%

of class CY24 spend

View profile →

Posaconazole

Brand: NOXAFIL · 70K Part D claims (CY24) · 21K beneficiaries · First FDA approval: 2006-09-15

19 generic mfrs 481 plans require PA Discontinued

Low NADAC$2.44

→

Avg plan cost$2.44

Part D spend $72.7M 1× spread, current vs floor

Class share

15%

of class CY24 spend

View profile →

Fluconazole

Brand: Diflucan · 5.7M Part D claims (CY24) · 3.5M beneficiaries · First FDA approval: 1993-12-23

17 generic mfrs 82 plans require PA

Low NADAC$0.213

→

Avg plan cost$0.348

Part D spend $55.1M 2× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Clotrimazole

Brand: CLOTIC (clotrimazole) otic solution · 1.6M Part D claims (CY24) · 950K beneficiaries · First FDA approval: 1993-08-31

10 generic mfrs 0 plans require PA

Low NADAC$0.138

→

Avg plan cost$0.264

Part D spend $33.8M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Voriconazole

Brand: VFEND · 58K Part D claims (CY24) · 21K beneficiaries · First FDA approval: 2002-05-24

21 generic mfrs 836 plans require PA Discontinued

Low NADAC$0.378

→

Avg plan cost$1.35

Part D spend $19.9M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Itraconazole

Brand: SPORANOX · 58K Part D claims (CY24) · 26K beneficiaries · First FDA approval: 1992-09-11

8 generic mfrs 69 plans require PA Discontinued

Low NADAC$0.838

→

Avg plan cost$4.32

Part D spend $11.6M 5× spread, current vs floor

Class share

of class CY24 spend

View profile →

Terconazole

190K Part D claims (CY24) · 135K beneficiaries · First FDA approval: 2004-04-06

3 generic mfrs 0 plans require PA

Low NADAC$0.563

→

Avg plan cost$8.98

Part D spend $5.6M 16× spread, current vs floor

Class share

of class CY24 spend

View profile →

Oteseconazole

Brand: VIVJOA · 174 Part D claims (CY24) · 157 beneficiaries · First FDA approval: 2022-07-11

Brand-only (no generics) 13 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $504036

Class share

of class CY24 spend

View profile →

Miconazole

Brand: Oravig · 4K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 1995-01-18

1 generic mfrs 0 plans require PA

Low NADAC$13.98

→

Avg plan cost$13.98

Part D spend $211372 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Luliconazole

Brand: Luzu · 646 Part D claims (CY24) · 382 beneficiaries · First FDA approval: 2013-11-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $139043

Class share

of class CY24 spend

View profile →

Clotrimazole Topical

Brand: Clotrimazole · — Part D claims (CY24) · First FDA approval: 2019-02-18

Brand-only (no generics)

Low NADAC$0.517

→

Avg plan cost$0.517

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Clotrimazole Topical Solution Usp,

— Part D claims (CY24) · First FDA approval: 2019-07-25

Brand-only (no generics) 0 plans require PA

Low NADAC$0.517

→

Avg plan cost$0.517

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Clotrimazole and Betameth

— Part D claims (CY24) · First FDA approval: 2023-10-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Clotrimazole and Betamethasone Dipropionate

— Part D claims (CY24) · First FDA approval: 2001-05-29

4 generic mfrs 0 plans require PA

Low NADAC$0.181

→

Avg plan cost$0.492

Part D spend — 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Fluconazole In Sodium

— Part D claims (CY24) · First FDA approval: 2006-04-17

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ketoconazole Cream

— Part D claims (CY24) · First FDA approval: 2023-02-07

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ketoconazole Foam

Brand: Ketoconazole · — Part D claims (CY24) · First FDA approval: 2021-05-21

Brand-only (no generics)

Low NADAC$2.78

→

Avg plan cost$4.59

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Posaconazole Delayed-Release

Brand: POSACONAZOLE · — Part D claims (CY24) · First FDA approval: 2019-08-28

Brand-only (no generics)

Low NADAC$2.44

→

Avg plan cost$2.44

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Vixa Skineal Compound Ketoconazole

Brand: Vixa Skineal · — Part D claims (CY24) · First FDA approval: 2024-06-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.